Real estate agent working in his office, he is writing a contract and house model on the foreground: investments, home loan and insurance concept

Prelude Therapeutics Announces Pricing of Initial Public Offering Nasdaq:PRLD


WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Prelude, before deducting underwriting commissions and offering expenses, are expected to be approximately $158.2 million. All of the shares of common stock are being offered by Prelude Therapeutics. In addition, Prelude Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,248,750 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on September 25, 2020 under the ticker symbol “PRLD.” The offering is expected to close on September 29, 2020, subject to the satisfaction of customary closing conditions.

Morgan Stanley,…

Click here for the full story.

Goldman Says Markets Overestimating Election Result Delay Risk By Bloomberg

Previous article

China Buying Spree Revives Export Profits for Top Crop Traders By Bloomberg

Next article

You may also like

Leave a Reply

Notify of

More in Earnings